<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Behav Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Behav Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Behavioural pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0955-8810</issn><issn pub-type="epub">1473-5849</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12226226</article-id><article-id pub-id-type="pmcid-ver">PMC12226226.1</article-id><article-id pub-id-type="pmcaid">12226226</article-id><article-id pub-id-type="pmcaiid">12226226</article-id><article-id pub-id-type="manuscript-id">NIHMS2067065</article-id><article-id pub-id-type="pmid">40272204</article-id><article-id pub-id-type="doi">10.1097/FBP.0000000000000823</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS2067065</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA2067065</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Gabapentin and D-cycloserine alone and in combination with naloxone in methadone-maintained humans responding under a naloxone novel-response discrimination procedure<sup><xref rid="FN3" ref-type="fn">1</xref></sup></article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>FITZGERALD</surname><given-names initials="LR">Lauren R.</given-names></name><xref rid="FN1" ref-type="author-notes">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>STANLEY</surname><given-names initials="NC">Nichole C.</given-names></name><xref rid="FN2" ref-type="author-notes">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>GUISE</surname><given-names initials="JB">Joseph B.</given-names></name><xref rid="FN1" ref-type="author-notes">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>CARGILE</surname><given-names initials="CS">Christopher S.</given-names></name><xref rid="FN1" ref-type="author-notes">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>MANCINO</surname><given-names initials="MJ">Michael J.</given-names></name><xref rid="FN1" ref-type="author-notes">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>OLIVETO</surname><given-names initials="AH">Alison H.</given-names></name><xref rid="CR1" ref-type="corresp">2</xref></contrib><aff id="A1">University of Arkansas for Medical Sciences, Little Rock, AR</aff></contrib-group><author-notes><fn fn-type="present-address" id="FN1"><label>3</label><p id="P1"><underline>Present Address:</underline> Department of Psychiatry and Behavioral Sciences, University of Arkansas for Medical Sciences, 4301 W Markham St., Slot 843, Little Rock, AR 72205 USA</p></fn><fn fn-type="present-address" id="FN2"><label>4</label><p id="P2"><underline>Present Address</underline>: Arkansas Center for Health Improvement, 1401 W. Capitol Avenue, Suite 300, Victory Building, Little Rock, AR 72201 USA</p></fn><corresp id="CR1"><label>2</label>Correspondence/Reprints/Current Address: Alison Oliveto, Ph.D., University of Arkansas for Medical Sciences, 4301 W. Markham St., Slot 843, Little Rock, AR 72205, FAX: 1 (501) 526-7816, <email>olivetoalison@uams.edu</email></corresp></author-notes><pub-date pub-type="ppub"><day>01</day><month>8</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>08</day><month>4</month><year>2025</year></pub-date><volume>36</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">492224</issue-id><fpage>265</fpage><lpage>275</lpage><pub-history><event event-type="nihms-submitted"><date><day>12</day><month>04</month><year>2025</year></date></event><event event-type="pmc-release"><date><day>08</day><month>04</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-07-04 20:25:29.300"><day>04</day><month>07</month><year>2025</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-2067065.pdf"/><abstract id="ABS1"><p id="P3">The present study examined the impact of the N-type calcium channel blocker gabapentin (GBP) and the partial glycine agonist d-cycloserine (CYC) to attenuate the behavioral effects of naloxone in opioid-dependent humans responding under a naloxone discrimination procedure. Methadone-maintained participants were trained to distinguish between a low dose of naloxone (0.15 mg/70 kg, i.m.; i.e., Drug A) and placebo (i.e., Drug B) under an instructed novel-response drug discrimination procedure, in which participants identify the drug condition as &#8220;A&#8221;, &#8220;B&#8221;, or &#8220;N&#8221; (neither A nor B - &#8216;novel&#8217;). Once the discrimination was acquired, doses of CYC (0, 500, 625 mg) and GBP (0, 100, 200, 400 mg) each alone and in combination with the training dose of naloxone were tested. GBP alone produced only placebo-appropriate responding and did not significantly alter naloxone discrimination when co-administered with naloxone, though it modestly reduced naloxone-induced visual analog scale ratings of drug &#8220;strength.&#8221; CYC alone also produced predominantly placebo-appropriate responding and did not modulate naloxone-appropriate responding, but increased ratings of bad effects and decreased ratings of like placebo relative to naloxone alone at the 500 mg dose. These null findings regarding modulation of naloxone discrimination highlight limited efficacy of GBP and CYC in this context, contributing to the understanding of pharmacological interactions with opioid antagonists and their potential implications for opioid withdrawal treatment.</p></abstract><kwd-group><kwd>Drug discrimination</kwd><kwd>Humans</kwd><kwd>Gabapentin (GBP)</kwd><kwd>D-cycloserine (CYC)</kwd><kwd>Naloxone</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-exception-type</meta-name><meta-value>EMBARGO</meta-value></custom-meta><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>4</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>no</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>